FDA warns Chengdu Brilliant over CGMP failures in semaglutide API, including no process validation and missing raw-material identity tests.
What happened
FDA reviewed records the company submitted in response to a March 12, 2025, request for records under section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act. FDA found no process validation for the semaglutide API and no identity testing of incoming raw materials for a period redacted in the letter. FDA placed all drugs offered for import from the firm on Import Alert 66-40 on July 9, 2025.
What FDA found
The firm did not perform process validation for its semaglutide API, so it lacks evidence that the process can reproducibly meet quality attributes.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The firm did not test the identity of each batch of incoming raw material used to make its API during a period redacted in the letter.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
What FDA wants
Respond in writing within 15 working days with what you have done to correct the deviations and prevent recurrence, or explain the delay and give a completion schedule. Provide the detailed validation and material-system information requested in the letter.
Who should pay attention
- drug manufacturers using semaglutide API from this firm
- companies with products listing this firm as an API manufacturer
- suppliers and distributors of imported APIs
This is a summary. Read the original letter on fda.gov.